OverviewChartNewsTraderScreen

UC BON.CERT. BAYN/  DE000HD5NJA0  /

gettex Zertifikate
10/31/2024  1:46:55 PM Chg.- Bid2:52:54 PM Ask- Underlying Strike price Expiration date Option type
25.060EUR - 24.990
Bid Size: 20,000		 -
Ask Size: -		 BAYER AG NA O.N. - - 12/31/2024 Call
TeleTrader 8/16 Bayer jumps 10% after Roundup court win
GlobeNewswire 8/2 Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting A...
GlobeNewswire 7/11 AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational...
GlobeNewswire 6/25 AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
GlobeNewswire 5/30 Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire 5/30 BlueRock Therapeutics receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’...
GlobeNewswire 5/29 Lynch Carpenter Investigates Claims in Cencora, Inc. Data Breach
GlobeNewswire 5/28 Pairwise and Bayer Expand CRISPR Leafy Greens Market through Licensing Agreement
TeleTrader 5/14 Bayer's sales in Q1 at €13.7 billion, down 4.3%
GlobeNewswire 5/2 AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting...
GlobeNewswire 4/18 AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in conge...
GlobeNewswire 4/16 AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’...
GlobeNewswire 4/11 Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from...
GlobeNewswire 4/9 AskBio Names Mansuo Shannon Chief Scientific Officer
GlobeNewswire 3/25 BlueRock Therapeutics and Foundation Fighting Blindness announce collaboration to expand the Uni-Rar...
GlobeNewswire 3/14 Bayer and Aignostics to collaborate on next generation precision oncology
GlobeNewswire 3/6 BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive tren...
TeleTrader 3/5 Bayer's Q4 sales at €11.9 billion
GlobeNewswire 3/4 BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
TeleTrader 3/4 Earnings preview: Bayer, Broadcom among those in calendar
GlobeNewswire 2/15 2Blades Delivers on Project with Bayer Crop Science to Combat Asian Soybean Rust
GlobeNewswire 2/13 Corporate Alignment with Climate Goals Under Scrutiny: LyondellBasell & Bayer demonstrate good pract...
GlobeNewswire 2/13 First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
TeleTrader 1/29 Bayer down over 5% after latest $2.25B Roundup ruling
TeleTrader 1/17 Bayer to cut jobs amid 'difficult situation'